POCD Research: Mitochondria as a Therapeutic Target

Every year, millions of older adults undergo surgery and emerge from the operating room facing an unexpected complication — not a wound infection or a cardiovascular event, but a measurable decline in memory, attention, and executive function. This condition, known as postoperative cognitive dysfunction (POCD), is far more common than many patients or even clinicians realize. A comprehensive 2026 review published in Molecular Neurobiology by Zhang, Zhao, Fan, and colleagues is now shedding new light on what may be driving this condition at the cellular level — and pointing toward targeted therapeutic strategies that could one day change how we protect the aging brain around the time of surgery.

What This Study Found

The review by Zhang et al. (2026) synthesizes a growing body of preclinical evidence suggesting that mitochondrial dysfunction sits at the center of POCD pathophysiology. Mitochondria, often described as the powerhouses of the cell, do far more than generate energy. They regulate calcium signaling, control the production of reactive oxygen species (ROS), and serve as gatekeepers for cell death pathways. When surgery, anesthesia, and the systemic stress response conspire to dysregulate these organelles, the consequences in vulnerable neurons can be profound.

Specifically, the researchers identified four interconnected mechanisms through which mitochondrial impairment appears to contribute to POCD:

• Disrupted energy metabolism: Neurons are among the most metabolically demanding cells in the body. The study suggests that surgical stress impairs mitochondrial ATP production, leaving neurons energetically depleted at a time when repair and recovery demand the most resources.
• Excessive reactive oxygen species (ROS) production: Researchers found that dysfunctional mitochondria generate abnormally high levels of ROS, contributing to oxidative stress that can damage lipids, proteins, and DNA within neurons.
• Calcium imbalance: Mitochondria play a critical buffering role in intracellular calcium homeostasis. The review highlights evidence that perioperative stressors can disrupt this balance, triggering cascades that promote neuronal injury.
• Abnormalities in mitochondrial dynamics and quality control: Healthy mitochondria constantly fuse and divide in a tightly regulated process. The study notes that POCD is associated with disruptions in these dynamics, as well as in mitophagy — the cellular process that removes damaged mitochondria before they cause further harm.

Together, these mitochondrial impairments are thought to trigger downstream neuroinflammation and activate multiple programmed cell death pathways, compounding cognitive injury in the postoperative period.

The review also evaluated several mitochondria-targeted therapeutic agents studied in preclinical models. Among the most highlighted were:

• SS-31 (Elamipretide): A mitochondria-targeted peptide that the study suggests may protect the inner mitochondrial membrane, reduce ROS overproduction, and support ATP synthesis. Researchers noted neuroprotective effects in animal models of POCD.
• Mdivi-1: A small molecule that inhibits excessive mitochondrial fission, potentially preventing the fragmentation of mitochondria that precedes neuronal death.
• P110: A peptide inhibitor targeting aberrant mitochondrial fission through a different mechanism, also showing preclinical promise in reducing neurological injury.
• NLRP3 inhibitors: These agents target the NLRP3 inflammasome, a key driver of neuroinflammation that the study links directly to mitochondrial ROS signaling in the context of POCD.

It is critical to note that the evidence reviewed is largely preclinical — derived from animal studies and in vitro models. The authors acknowledge that robust human clinical trial data is still needed before any of these agents can be recommended for clinical use in POCD prevention or treatment.

Clinical Significance

POCD is not a trivial or transient phenomenon. Zhang et al. emphasize that it represents a substantial burden on quality of life and healthcare systems, particularly given the rapid growth of the older surgical population globally. Patients who develop POCD face increased risks of long-term cognitive decline, loss of independence, prolonged hospitalization, and greater caregiver demands.

What makes this review particularly significant is its framing of mitochondrial health as a modifiable therapeutic target — a shift from viewing POCD as an inevitable consequence of aging and anesthesia. By identifying specific molecular pathways, the research opens conceptual doors for intervention strategies that could be deployed before, during, or after surgery to reduce neurological injury risk.

The authors also explore the potential of multi-target combinational treatments and time-specific interventions, recognizing that the perioperative window may offer distinct opportunities — for example, preoperative mitochondrial priming versus postoperative inflammatory dampening. They further discuss the promise of individualized therapeutic approaches, acknowledging that POCD risk and mitochondrial vulnerability are not uniform across all older patients.

However, the review is candid about the challenges ahead. Key barriers to clinical translation include limited blood-brain barrier permeability for many candidate agents, potential unintended drug effects, and significantly altered pharmacokinetics in elderly populations — meaning that dosing strategies validated in younger animal models may not translate directly to the patients who need these therapies most.

Current Access and Compliance Context

Among the therapeutic agents reviewed, SS-31 (Elamipretide) has attracted considerable attention in the broader peptide research community for its mitochondrial targeting properties. It is currently under investigation in clinical trials for conditions including heart failure with preserved ejection fraction and Barth syndrome, though its application specifically to POCD remains in the preclinical stage.

The emerging role of nanocarrier drug-delivery systems, highlighted by Zhang et al., represents a particularly exciting frontier. These technologies may eventually help overcome the blood-brain barrier permeability problem — one of the most persistent obstacles in central nervous system pharmacology. The authors also discuss AI-guided personalized treatment planning as a tool for identifying which patients are at highest mitochondrial risk and tailoring interventions accordingly.

For patients and clinicians interested in this emerging space, working with a physician knowledgeable in peptide therapies and mitochondrial medicine is essential. The field is evolving rapidly, and appropriate medical oversight is critical to ensuring that any investigational approaches are pursued safely and within an evidence-informed framework.

What Patients Should Know

If you or a loved one is an older adult facing a planned surgical procedure, the prospect of POCD is worth discussing with your care team — particularly if there are pre-existing concerns about cognitive health. While no mitochondria-targeted therapies are currently approved for POCD prevention based on the current state of the evidence, awareness of the mechanisms involved can help inform conversations about perioperative care optimization.

General mitochondrial health strategies — including adequate nutrition, management of metabolic risk factors, regular physical activity, and minimizing unnecessary oxidative stressors — are broadly supported by existing evidence and represent a reasonable foundation while the field advances.

Patients should also know that the research landscape is moving quickly. The peptide SS-31, in particular, represents an example of how mitochondria-targeted molecules are progressing through scientific evaluation. Staying connected with physicians who monitor the peptide and mitochondrial medicine literature can be valuable as clinical evidence continues to develop.

Conclusion

The 2026 review by Zhang and colleagues represents an important synthesis of our current understanding of POCD through a mitochondrial lens. By mapping the specific pathways through which mitochondrial dysfunction drives neuroinflammation and cell death in the postoperative brain — and by identifying promising therapeutic candidates like SS-31, Mdivi-1, P110, and NLRP3 inhibitors — this research offers a scientifically grounded roadmap for future investigation. While human clinical trial data remains essential before any clinical recommendations can be made, the mechanistic clarity provided by this review represents meaningful progress toward protecting the cognitive health of aging surgical patients.

If you are interested in learning more about peptide-based therapies and working with a clinician who stays current with emerging research in this field, visit peptideassociation.org/find-a-doctor to find a qualified healthcare provider near you.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The therapies discussed in this article are investigational and not approved by the FDA for the prevention or treatment of postoperative cognitive dysfunction. Always consult a qualified healthcare professional before making any decisions about your medical care or treatment options.

---

Citation: Zhang A, Zhao A, Fan G, et al. Targeting Mitochondria for Postoperative Cognitive Dysfunction: From Mechanisms to Therapeutics. Molecular Neurobiology. 2026;63(8). doi:10.1007/s12035-026-06120-3. PMID: 42570043.